The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development

Vaccine. 2012 Jan 5;30(2):225-30. doi: 10.1016/j.vaccine.2011.11.010. Epub 2011 Nov 10.


We have recently shown that immunization against the extra domain-B (ED-B) of fibronectin, using Freund's adjuvant, reduces tumor growth in mice by 70%. In the present study we compare the immune response generated against ED-B using the non-toxic and biodegradable adjuvant Montanide ISA 720/CpG with the response elicited by Freund's adjuvant. Montanide ISA 720/CpG induced anti-ED-B antibodies with higher avidity and less variable levels between individuals than Freund's. Moreover, the duration of the immune response was longer and the generation of anti-ED-B antibodies in naïve mice was faster, when Montanide ISA 720/CpG was used. We conclude that it is possible to replace the mineral oil based adjuvant Freund's with an adjuvant acceptable for human use, which is a prerequisite for transfer of the ED-B vaccine to the clinic.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Adjuvants, Immunologic / adverse effects
  • Animals
  • Antibodies, Neoplasm / blood
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / immunology*
  • Female
  • Fibronectins / antagonists & inhibitors*
  • Fibronectins / immunology*
  • Freund's Adjuvant / administration & dosage*
  • Freund's Adjuvant / adverse effects
  • Mannitol / administration & dosage
  • Mannitol / adverse effects
  • Mannitol / analogs & derivatives*
  • Mice
  • Mice, Inbred C57BL
  • Oleic Acids / administration & dosage*
  • Oleic Acids / adverse effects
  • Protein Structure, Tertiary


  • Adjuvants, Immunologic
  • Antibodies, Neoplasm
  • Cancer Vaccines
  • Fibronectins
  • Oleic Acids
  • mannide monooleate
  • Mannitol
  • Freund's Adjuvant